Skip to content

MiLoCoDaS - Mild to Moderate Long Covid Digital Intervention Study

MiLoCoDaS - Mild to Moderate Long Covid Digital Intervention Study - MiLoCoDaS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00028964
Enrollment
600
Registered
2022-08-24
Start date
2023-03-21
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post COVID-19 disease according to Delphi consensus G93.3 U08.9 U09.9

Interventions

Group 1: High intensity: 12-week online workshop (webinar) in a closed group in combination with a 12-week interactive digital self-learning course that teaches similar content in a specially configur

Sponsors

Zentrum für Präventivmedizin und Digitale Gesundheit (CPD), Abteilung Allgemeinmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 67 Years

Inclusion criteria

Inclusion criteria: a) Patients with concurrent SARS-CoV-2 infection (prevention criterion): Patients requiring continuation of the medically certified sick-leave due to persistence of symptoms beyond day 7 after initial diagnosis, but whose symptom severity does not lead to hospitalisation or immediate specialist therapy. b) Patients with previous onset of Covid-19 (treatment criterion): Adult patients, aged 18 to 67 years, who present (again) to a participating GP practice and have had SARS-CoV-2 infection detected by antigen or PCR testing for at least three months and no more than 12 months prior to this consultation. The patients have associated symptoms that have lasted for at least two months and cannot be explained by any other diagnosis (WHO definition of post-COVID-19 condition). Equivalent is the assignment of ICD-10 diagnosis codes U08.9 and U09.9 within the defined time frame. In the investigator's interview, the patient's medical history shows an impairment of daily life caused by persistent COVID-19 symptoms documented via screening questions on daily activities and general health (unweighted sum, cut-off: score of at least 20% less compared to before the infection).

Exclusion criteria

Exclusion criteria: Relevant impairment due to symptomatic cancer. Chemotherapeutic treatment of malignant or autoimmune disease. Known psychiatric disorder. Neurological disease, especially if affecting cognition (previous stroke, dementia, etc.). Alternative medical explanation for symptoms. Severe impairment due to Long Covid symptoms, defined by the associated need for hospitalisation. No access to a stable internet connection with sufficient bandwidth for video telephony. No access to an internet-connected device. Persons not capable of giving consent themselves. Persons with significant difficulties in understanding spoken and/or written German.

Design outcomes

Primary

MeasureTime frame
Sick-leave days or workplace reintegration days (german BEM-programme) with less than 50% working time. Reported by attending GP.

Secondary

MeasureTime frame
Change in quality of life after 3 and 6 months compared to baseline. Change in impairment of core work ability and work productivity after 3 and 6 months compared to baseline. Change in questionnaire scales and after 3 and 6 months compared to baseline. (Correction for multiple measurements). Use of resources.

Countries

Germany

Contacts

Public ContactAdrian Krotz

Zentrum für Präventivmedizin und Digitale Gesundheit (CPD), Abteilung Allgemeinmedizin

adrian.krotz@medma.uni-heidelberg.de+4962138371817

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026